Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function

Reviews in Cardiovascular Medicine

Volumn 7, Issue SUPPL. 4, 2006, Pages

  Kereiakes, Dean J ^a,b  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Abciximab; Coronary microvascular function; GP IIb IIIa inhibitors; Percutaneous coronary intervention; Platelet aggregation; Vascular inflammation

Indexed keywords

ABCIXIMAB; C REACTIVE PROTEIN; CD11B ANTIGEN; CD18 ANTIGEN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; MONOCLONAL ANTIBODY XT 199; PLACEBO; TIROFIBAN; UNCLASSIFIED DRUG; VITRONECTIN; XT 199;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL FUNCTION; BLOOD VESSEL INJURY; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; FIBRINOLYSIS; HEART MUSCLE PERFUSION; HUMAN; IN-STENT RESTENOSIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; RECEPTOR AFFINITY; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; CORONARY CIRCULATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTEGRIN ALPHAVBETA3; MACROPHAGE-1 ANTIGEN; MICROCIRCULATION; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; VASCULITIS;

EID: 33846498466     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Quinn M, Deering A, Stewart M, et al. Quantifying GP IIb/IIIa receptor binding using 2 monoclonal antibodies. Circulation. 1999;99:2231-2238.
2. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoproteins IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation. 1999;100:437-444.
3. Jordan RE, Wagner CL, Mascelli G, et al. Pre-clinical development of c73E Fab. In: Horton M, ed. Adhesion Receptors as Therapeutic Targets. Boca Raton, FL: CRC Press; 1996:281-305.
4. Mousa SA, Bennett JS. Platelets in health and disease: platelet GP IIb/ IIIa structure and function: recent advances in antiplatelet therapy. Drugs Future. 1996;21:1141-1154.
5. Mascelli MA, Lance ET, Damaraju L, et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation. 1998;97:1680-1688.
6. Coller BS. Potential non-glycoprotein IIb/IIIa effects of abciximab. Am Heart J. 1999;138(suppl.): S1-S5.
7. Kereiakes DJ, Runyon JP, Broderick TM, Shimshak TM. IIb's are not IIb's. Am J Cardiol. 2000;85:23C-31C.
8. Kereiakes DJ, Anderson KM, Achenbach RE, et al. Abciximab survival advantage is not explained by reduction in early major cardiac events: EPIC, EPILOG and EPISTENT 3 year analysis [abstract]. Circulation. 2001;104:II-87.
9. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. EPIC, EPILOG and EPISTENT Investigators. Am J Med. 2002;113:1-6.
10. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation. 2002;106:804-808.
11. Lombardo A, Biasucci LM, Lanza GA, et al. Inflammation as a possible link between coronary and carotid plaque instability. Circulation. 2004;109:3158-3163.
12. Fleiner M, Kummer M, Mirlacher M, et al. Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation. 2004; 110:2843-2850.
13. Moreno PR, Purushothaman KR, O'Connor WN, et al. Increased inflammation and neovascularization in diabetes atherosclerosis is no longer present in fibrocalcific plaques: a marker of stabilization [abstract]? J Am Coll Cardiol. 2005;45:402A.
14. Mauriello A, Sangiorgi G, Fratoni S, et al. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol. 2005;45:1585-1593.
15. Goldstein JA, Chandra HA, O'Neill WW. Relation of number of complex coronary lesions to serum C-reactive protein levels and major adverse cardiovascular events at one year. Am J Cardiol. 2005;96:56-60.
16. Tanaka A, Shimada K, Sano T, et al. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J Am Coll Cardiol. 2005; 45:1594-1599.
17. Altwegg LA, Corti R, von Eckardstein A, et al. Interleukin-6 but not C-reactive protein is elevated at the site of ruptured plaques in acute coronary syndromes [abstract]. J Am Coll Cardiol. 2004;43:282A.
18. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
19. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107:1783-1790.
20. Libby P. Act local, act global: inflammation and the multiplicity of "vulnerable" coronary plaques. J Am Coll Cardiol. 2005; 45:1600-1602.
21. Inoue T, Kato T, Uchida T, et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol. 2005;46:239-245.
22. Farb A, Weber DK, Kolodgie FD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974-2980.
23. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44-52.
24. Aggarwal A, Schneider DJ, Terrien EF, et al. Increase in interleukin-6 in the first hour after coronary stenting: an early marker of the inflammatory response. J Thromb Thrombolysis. 2003;15:25-31.
25. Aggarwal A, Blum A, Schneider DJ, et al. Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. Coron Artery Dis. 2004;15:471-475.
26. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106:896-899.
27. Cipollone F, Ferri C, Desideri G, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation. 2003;108:2776-2782.
28. Szmitko PE, Wang CH, Weisel RD, et al. New markers of inflammation and endothelial cell activation: part I. Circulation. 2003;108:1917-1923.
29. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104-1111.
30. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol. 1998;82:515-518.
31. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation. 2001;104:163-167.
32. Merino A, Segura I, Vida B, et al. Eptifibatide blocks C-reactive protein increase after coronary angioplasty [abstract]. J Am Coll Cardiol. 2003;41:233A.
33. Welt FG, Rogers SD, Zhang X, et al. GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Catheter Cardiovasc Interv. 2004;61:185-189.
34. Dalby M, Montalescot G, Bal dit Sollier C, et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel: results of the Platelet Activity Extinction in Non-Q-wave Myocardial Infarction with Aspirin, Clopidogrel, and Eptifibatide (PEACE) study. J Am Coll Cardiol. 2004;43:162-168.
35. Keating FK, Dauerman HL, Whitaker DA, et al. The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis. 2005;16:401-405.
36. Keating FK, Dauerman HE, Whitaker DA, et al. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res. 2006;118:361-369.
37. Coller BS. Binding of abciximab to αVβ3 and activated αMβ2 receptors: with a review of platelet-leukocyte interactions. Thromb Haemost. 1999;82:326-335.
38. Tam Sh, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(V)beta3 integrins. Circulation. 1998;98:1085-1091.
39. Stouffer GA, Hu Z, Sajid M, et al. Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation. 1998;97:907-915.
40. Byzova TV, Rabbani R, D'Souza SE, Plow EF. Role of integrin alpha(V)beta3 in vascular biology. Thromb Haemost. 1998;80:726-734.
41. Hoshiga M, Alpers CE, Smith LL, et al. Alpha-V beta-3 integrin expression in normal and atherosclerotic artery. Circ Res. 1995;77:1129-1135.
42. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced, thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest. 1996;98:863-874.
43. Furman MI, Krueger LA, Frelinger AL 3rd, et al. GP IIb/IIIa antagonist-induced reduction in platelet surface V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost. 2000:84:492-498.
44. Bishop GG, McPherson JA, Sanders JM, et al. Selective alpha(V)beta(3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation. 2001;103:1906-1911.
45. Srivatsa SS, Fitzpatrick LA, Tsao PW, et al. Selective αVβ3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin αVβ3 and osteopontin expression during neointima formation. Cardiovasc Res. 1997; 36:408-428.
46. Lincoff AM, Moliterno DJ, Ellis SG, et al. Six month angiographic outcome with abcximab and stents: the EPISTENT angiographic substudy [abstract]. Circulation. 1998;98:I-768.
47. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
48. Mehilli J, Kastrati A, Schuhlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation. 2004;110;3627-3635.
49. Mickelson JK, Ali MN, Kleiman NS, et al. Chimeric 7E3 Fab (ReoPro) decreases detectable CDllb on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol. 1999; 33:97-106.
50. Serrano CV Jr, Ramires JA, Venturinelli M, et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression: evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol. 1997;29:1276-1283.
51. Inoue T, Uchida T, Yaguchi I, et al. Stent-induced expression and activation of the leukocyte integrin mac-1 is associated with neointimal thickening and restenosis. Circulation. 2003;107; 1757-1763.
52. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/ IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915-921.
53. Seshiah PN, Kereiakes, DJ, Vasudevan SS, et al. Activated monocytes induce smooth muscle cell death: role of macrophage colony-stimulating factor and cell contact. Circulation. 2002;105; 174-180.
54. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105;1135-1143.
55. Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993;69:377-381.
56. Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106:2894-2900.
57. Schaar JA, De Korte CL, Mastik F, et al. Characterizing vulnerable plaque features with intravascular elastography. Circulation. 2003;108: 2636-2641.
58. Saitoh T, Kishida H, Tsukada Y, et al. Clinical significance of increased plasma concentration of macrophage colony-stimulating factor in patients with angina pectoris. J Am Coll Cardiol. 2000:35:655-665.
59. Ikonomidis I, Andreotti F, Eonomou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100:793-798.
60. Kereiakes DJ, Lincoff AM, Anderson K, et al. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. EPIC, EPILOG and EPISTENT Investigators. Am J Cardiol. 2002:90:628-630.
61. Godicke J, Flather M, Noc M, et al. Early versus 4periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. Am Heart J. 2005;150:1015.
62. Maioli M, Bellandi F, Leoncini M, et al. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI study). Am J Cardiol. 2006 (in press).
63. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 1998;98:2695-2701.
64. Aymong ED, Curtis MJ, Youssef M, et al. Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting. Circulation. 2002;105:2981-2985.
65. Marzilli M, Sambuceti G, Testa R, Fedele S. Platelet glycoprotein IIb/ IIIa receptor blockade and coronary resistance in unstable angina. J Am Coll Cardiol. 2002;40:2102-2109.
66. Feldman LJ, Coste P, Furber A, et al. Incomplete resolution of ST-segment elevation is a marker of transient microcirculatory dysfunction after stenting for acute myocardial infarction. Circulation. 2003;107:2684-2689.
67. Goto S, Tamura N, Ishida H. Ability of antiglycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol. 2004;44:316-323.
68. Marciniak SJ Jr, Mascelli MA, Furman MI, et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002;87:1020-1025.
69. Carry M, Korley V, Willerson JT, et al. Increased urinary leukotriene excretion in patients with cardiac ischemia: in vivo evidence for 5-lipoxygenase activation. Circulation. 1992;85:230-236.
70. Sala A, Rossoni G, Berti F, et al. Monoclonal anti-CD18 antibody prevents transcellular biosynthesis of cysteinyl leukotrienes in vitro and in vivo and protects against leukotriene-dependent increase in coronary vascular resistance and myocardial stiffness. Circulation. 2000;101:1436-1440.
71. Barrabes JA, Garcia-Dorado D, Mirabet M, et al. Lack of effect of glycoprotein IIb/IIIa blockade on myocardial platelet or polymorphonuclear leukocyte accumulation and on infarct size after transient coronary occlusion in pigs. J Am Coll Cardiol. 2002;39:157-165.
72. Furman MI, Krueger LA, Frelinger AL, et al. Tirofiban and eptifibatide, but not abciximab, induce leukocyte-platelet aggregation [abstract]. Circulation. 1999;100:I-681.
73. Furman MI, Kereiakes DJ, Krueger LA, et al. Leukocyte-platelet aggregation and platelet p-selectin and GP IIIa expression following percutaneous coronary intervention: effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J. 2001;142: 790-798.